Epithelial Membrane Protein-2 Expression Is an Early Predictor of Endometrial Cancer Development
O Habeeb, L Goodglick, RA Soslow, R Rao, O Schirripa, S Horvath, J Braun, DB Seligson, M Wadehra. David Geffen School of Medicine at UCLA, Los Angeles, CA; Memorial Sloan-Kettering Cancer Center, New York, NY
Background: Endometrial cancer (EC) is a common malignancy worldwide. It is often preceded by endometrial hyperplasia, whose management and risk of neoplastic progression vary. Previously, we have shown that the tetraspan protein, Epithelial Membrane Protein-2 (EMP2) is a prognostic indicator for EC aggressiveness and survival (Wadehra M, Natarajan S, Seligson DB, et al. 2006). Here we examine whether EMP2 expression within preneoplastic lesions is a prognostic biomarker for EC development.
Design: A tissue microarray was constructed with specimens from 207 patients. Staining intensity of EMP2 levels by immunohistochemistry was scored from 0 to 3. Appropriate statistical analyses revealed differences in EMP2 expression by histology, along with its impact on the risk of endometrial cancer development. Progression-related criteria and analyses focused on cases whose clinical outcome was known after at least one year to exclude underlying carcinoma (Lacey JV, Jr., Ioffe OB, Ronnett BM, et al. 2008; Kurman RJ, Kaminski PF, Norris HJ 1985).
Results: A single, mean pooled value for EMP2 across multiple, informative spots within each histology of a case was generated. By doing so, we discovered a step-wise, significant increase in the average spot- and case-level expression of EMP2 (see Figure 1). Moreover, detailed analysis of EMP2 expression in premalignant cases demonstrated that EMP2 positivity was a strong predictor for EC development (see Figure 2).
Conclusions: Combined with our previous findings, these results suggest that EMP2 is a novel biomarker for EC development and progression.
Category: Gynecologic & Obstetrics
Wednesday, March 24, 2010 9:30 AM
Poster Session V # 135, Wednesday Morning